T cell immunity to SARS-CoV-2 vaccination in inflammatory bowel disease patients treated with anti-cytokine biologics
The Journal of Immunology · 2026
DOI: 10.1093/jimmun/vkag173 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2026. Verfasst von Michelle W Cheung und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, SARS-CoV-2, COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Toronto, Canadian Institutes of Health Research (CIHR)/COVID-Immunity Task Force (CITF), CIHR Canada Graduate Scholarships Doctoral.
Abstract (Originalsprache)
Anti-TNF and anti-IL-12/IL-23 are commonly used therapies for immune-mediated inflammatory diseases (IMIDs), including inflammatory bowel disease (IBD). Although several studies have shown intact T cell responses following 2 to 3 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in biologics treated IMID patients, our group previously reported increased waning of T cell responses at 3–4 mos following the second vaccine dose in IMID patients compared to healthy controls, raising the possibility that a suboptimal initial T cell response could impact long term immunity. Here, to reduce patient heterogeneity, we focused only on IBD patients and further investigated T cell responses in vaccinated, untreated and biologics treated IBD patients compared to healthy controls. Following 1 vaccine dose, we observed a decreased frequency of Spike-reactive Th1 polarized cells and an increased frequency of Th2 cells in the IBD patients in general, relative to healthy controls. Additionally, IBD patients exhibited increased waning of Spike-specific cytokine T cell responses after 2 doses of vaccine. We also observed IBD-treatment specific effects. Spike-specific IL-2 secretion from anti-TNF or anti–IL-12/IL-23–treated patients’ T cells was lower than from untreated patients following 1 dose of vaccine. However, single-cell RNA-sequencing of Spike-responsive T cells from anti-TNF and anti–IL-12/IL-23 treated IBD patients and healthy controls 2–4 wk after 2 or 3 vaccine doses revealed no major differences in T cell subsets, transcriptomes or TCR diversity. Thus, despite some evidence of impaired primary T cell responses, Spike-reactive T cells in patients treated with anti-TNF or anti–IL-12/IL-23 appear indistinguishable from healthy controls following a full vaccine course.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
- Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.
- Zane Cohen Centre for Digestive Diseases, Division of Gastroenterology, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.
- Gladman Krembil Psoriatic Arthritis Program, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada.
- Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Vinod Chandran, Tania H Watts
Förderung
- University of Toronto
- Canadian Institutes of Health Research (CIHR)/COVID-Immunity Task Force (CITF)
- CIHR Canada Graduate Scholarships Doctoral
- Canada Research Chair in Anti-viral Immunity, University of Toronto
- Psoriatic Arthritis Research at UHN
Zitieren
APA
Cheung, M. W., Choi, J. D., Stempak, J. M., Chandran, V., Silverberg, M. S., & Watts, T. H. (2026). T cell immunity to SARS-CoV-2 vaccination in inflammatory bowel disease patients treated with anti-cytokine biologics. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkag173
Vancouver
Cheung MW, Choi JD, Stempak JM, Chandran V, Silverberg MS, Watts TH. T cell immunity to SARS-CoV-2 vaccination in inflammatory bowel disease patients treated with anti-cytokine biologics. The Journal of Immunology. 2026. doi:10.1093/jimmun/vkag173
BibTeX
@article{Cheung2026,
author = {Cheung, Michelle W and Choi, Jenny D and Stempak, Joanne M and Chandran, Vinod and Silverberg, Mark S and Watts, Tania H},
title = {T cell immunity to SARS-CoV-2 vaccination in inflammatory bowel disease patients treated with anti-cytokine biologics},
journal = {The Journal of Immunology},
year = {2026},
doi = {10.1093/jimmun/vkag173}
}
EUVIMED